瑞舒伐他汀与阿托伐他汀治疗冠心病的疗效和安全性比较
x

请在关注微信后,向客服人员索取文件

篇名: 瑞舒伐他汀与阿托伐他汀治疗冠心病的疗效和安全性比较
TITLE:
摘要: 目的:比较瑞舒伐他汀与阿托伐他汀治疗冠心病的疗效和安全性。方法:96例冠心病患者随机均分为观察组和对照组。所有患者对饮食进行合理控制,同时服用低分子肝素、阿司匹林肠溶片、β受体阻滞药和硝酸酯类药物等常规治疗,但不服用维生素等抗氧化药物。在此基础上,观察组患者给予瑞舒伐他汀钙片10 mg,口服,每日1次 ;对照组患者给予阿托伐他汀钙胶囊20 mg,口服,每日1次。两组患者疗程均为6个月。观察两组患者的临床疗效,治疗前后总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、超敏 C 反应蛋白(hs-CRP)和左心射血分数(LVEF)及不良反应发生情况。结果:两组患者总有效率、不良反应发生率比较,差异均无统计学意义(P>0.05)。治疗前,两组患者TC、TG、LDL-C、HDL-C、hs-CRP、 LVEF比较,差异均无统计学意义(P>0.05)。治疗后,两组患者TC、TG、LDL-C、hs-CRP均显著低于同组治疗前,且观察组TC、LDL-C、hs-CRP均低于对照组,HDL-C、LVEF均显著高于同组治疗前,且观察组均高于对照组,差异均有统计学意义(P<0.05)。结论:瑞舒伐他汀与阿托伐他汀治疗冠心病的疗效和安全性均相当,但瑞舒伐他汀在降低血脂方面优于阿托伐他汀。
ABSTRACT: OBJECTIVE:To compare the efficacy and safety of  rosuvastatin and atorvastatin in the treatment of coronary heart disease. METHODS: 96 patients with coronary heart disease were randomly divided into observation group and control group. All patients received  reasonable diet control, low molecular weight heparin, Aspirin enteric-coated tablet, β-blockers, nitric acid lipids and other conventional treatment, but no vitamins and other antioxidant drugs. Based on it, observation group was orally given 10 mg Rosuvastatin tablet, once a day; control group was given 20 mg Atorvastatin capsule, once a day. The treatment course for both groups was 6 months. Clinical efficacy, total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), high-sensitivity C-reactive protein (hs-CRP) and left ventricular ejection fraction (LVEF) before and after treatment, and the incidence of adverse reactions in 2 groups were observed. RESULTS: There were no significant differences in the total effective rate and incidence of adverse reactions between 2 groups(P>0.05). Before treatment, there were no significant differences in the TC,TG,LDL-C,HDL-C,hs-CRP and  LVEF between 2 groups(P>0.05). After treatment,TC,TG,LDL-C,HDL-C and hs-CRP in 2 groups were significantly lower than before, and TC, LDL-C and hs-CRP in observation group were lower than control group, HDL-C and LVEF in 2 groups were significantly higher than before, and observation group was higher than control group, the differences were statistically significant (P<0.05). CONCLUSIONS: Rosuvastatin and atorvastatin has similar efficacy and safety in the treatment of coronary heart disease, but rosuvastatin is superior to atorvastatin in terms of reducing lipid levels.
期刊: 2016年第27卷第12期
作者: 张理科,陈宇
AUTHORS: ZHANG Like,CHEN Yu
关键字: 瑞舒伐他汀;阿托伐他汀;冠心病;疗效;安全性
KEYWORDS: Rosuvastatin; Atorvastatin; Coronary heart disease; Efficacy; Safety
阅读数: 333 次
本月下载数: 5 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!